相关实验视频

Updated: Jun 12, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

向非编码RNA,以克服EGFR突变非小细胞肺癌中奥西默提尼布耐药性

Beilei Zeng^1,2, Kelun Gan¹, Yuanhang Yu¹

¹Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.

Frontiers in oncology

|September 26, 2024

概括

非小细胞肺癌 (NSCLC) 的奥西默提尼布耐药性是由非编码RNAs (ncRNAs) 驱动的. 了解这些ncRNAs为治疗EGFR突变的NSCLC抗奥西默提尼布的治疗提供了新的策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

奥西默提尼布是一种第三代EGFR氨酸激酶抑制剂,可改善EGFR突变NSCLC的存活率.
对奥西默蒂尼布的耐药性是NSCLC治疗中的重大临床挑战.

研究的目的:

审查非编码RNAs (ncRNAs) 在 osimertinib 耐药性机制中的作用.
突出ncRNAs在EGFR突变NSCLC中克服奥西默提尼布耐药性的临床潜力.

主要方法:

对研究ncRNAs和 osimertinib 耐药性的文献综述.
分析ncRNA在调节参与肺癌进展的信号通路中的功能.
综合目前对调节治疗敏感性的ncRNA机制的理解.

主要成果:

ncRNAs,包括microRNAs,长ncRNAs和圆形RNAs,都与NSCLC的发展和进展有关.
特定的ncRNAs通过改变对药物的敏感性,显著影响 osimertinib 耐药性.
ncRNAs调节关键信号通路,有助于药物耐药性的出现.

结论:

在EGFR突变的NSCLC中,ncRNAs代表了克服 osimertinib 耐药性的有前途的治疗标.
需要进一步的研究来将基于ncRNA的策略转化为有效的临床实践.
了解ncRNA功能对于开发抗性NSCLC的新型治疗方法至关重要.

关键词:

欧洲农业基金会 (EGFR) 是一个基金.这是一个机制机制.这是一个ncRNARNA.非小细胞肺癌的肺癌.奥西默蒂尼布的耐药性是异常的

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...